Purpose: The purpose of this study was to evaluate the ocular safety of a novel microfistula implant and its composite materials in an animal model.
Methods: The anterior chambers of 12 rabbit eyes were injected with either glutaraldehyde cross-linked porcine gelatin extract or balanced salt solution and were followed by serial slit lamp examinations over 3 days. The eyes of 18 canines underwent microfistula implantation or a sham procedure. The animals were monitored over the subsequent 12 months, using serial slit lamp examinations, indirect ophthalmoscopy, tonometry, specular microscopy, and high-resolution ultrasonography. Ocular tissues were examined histopathologically on postoperative days 7, 30, 90, 180, and 365.
Results: Glutaraldehyde cross-linked porcine gelatin did not induce significant intraocular inflammation in the rabbit model. The microfistula implant was well tolerated and did not stimulate significant tissue response in the canine eye. The microfistula tube did not undergo structural change or degradation over the course of the study.
Conclusions: In nonprimate mammals, the material composing the microfistula implant and the implant itself do not induce significant inflammation or tissue reaction.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1167/iovs.16-19453 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Outcomes of 45 μm gelatin stent surgery over 24-month follow-up.
Clin Exp Ophthalmol
January 2023
Lions Eye Institute, Perth, Western Australia, Australia.
Background: The main objectives of this study were to determine whether known risk factors for trabeculectomy failure similarly influence gelatin stent outcomes and to identify surgical factors which may optimise success.
Methods: A retrospective, observational study was conducted at a single centre in Perth, Western Australia over 24 months. Two-hundred and sixty-two eyes of 207 patients underwent XEN-45 stent surgery with various forms of glaucoma.
Long-Term Results Using Gelatin Microfistulae Implantation without Antimetabolite.
Ophthalmology
November 2018
Lions Eye Institute, University of Western Australia, Nedlands, Australia.
XEN-45 gelatin microfistula for uveitic glaucoma.
Clin Exp Ophthalmol
May 2018
Lions Eye Institute, Centre for Ophthalmology and Visual Science, University of Western Australia, Perth, Western Australia, Australia.
Biocompatibility of a Novel Microfistula Implant in Nonprimate Mammals for the Surgical Treatment of Glaucoma.
Invest Ophthalmol Vis Sci
July 2016
Department of Ophthalmology and Visual Sciences Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States.
Purpose: The purpose of this study was to evaluate the ocular safety of a novel microfistula implant and its composite materials in an animal model.
Methods: The anterior chambers of 12 rabbit eyes were injected with either glutaraldehyde cross-linked porcine gelatin extract or balanced salt solution and were followed by serial slit lamp examinations over 3 days. The eyes of 18 canines underwent microfistula implantation or a sham procedure.
Early Clinical Results of a Novel Ab Interno Gel Stent for the Surgical Treatment of Open-angle Glaucoma.
J Glaucoma
July 2016
*Department of Ophthalmology and Visual Sciences, Washington University School of Medicine in St. Louis, St. Louis, MO †Institute for Vision Science, Ruhr University Eye Hospital, Bochum, Germany ‡Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto §Credit Valley Eye Care ∥Trillium Health Partners, Mississauga, ON, Canada.
Purpose: To evaluate the intraocular pressure (IOP) lowering effect of the XEN140 microfistula gel stent implant for the surgical treatment of open-angle glaucoma.
Patients And Methods: Forty-nine eyes of 49 patients with an IOP>18 mm Hg and ≤35 mm Hg were studied in a prospective nonrandomized multicenter cohort trial of the surgical implantation of the XEN140 implant in patients with open-angle glaucoma. Complete success was defined as a postoperative IOP≤18 mm Hg with ≥20% reduction in IOP at 12 months without any glaucoma medications.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!